
|Podcasts|September 27, 2021
Highlighting results from first FDA-reported study for treatment of presbyopia
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Advertisement
Listen to the findings from the first FDA-reported study of a presbyopia-treatment eye drop.
George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Watch the interview:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD
3
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
4
Retina Society 2026: How blood biomarkers may predict GA speed
5










